| Title |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2014
|
| DOI | 10.2147/dddt.s56597 |
| Pubmed ID | |
| Authors |
Tadashi Sofue, Masashi Inui, Taiga Hara, Yoko Nishijima, Kumiko Moriwaki, Yushi Hayashida, Nobufumi Ueda, Akira Nishiyama, Yoshiyuki Kakehi, Masakazu Kohno |
| Abstract |
Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7.0 mg/dL or need for treatment with allopurinol or benzbromarone, reduces long-term allograft survival in kidney transplant recipients. Febuxostat, a new nonpurine selective xanthine oxidase inhibitor, is well tolerated in patients with moderate renal impairment. However, its efficacy and safety in kidney recipients with PTHU is unclear. We therefore assessed the efficacy and safety of febuxostat in stable kidney transplant recipients with PTHU. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 32% |
| Other | 3 | 11% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Bachelor | 2 | 7% |
| Professor | 2 | 7% |
| Other | 6 | 21% |
| Unknown | 3 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 54% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 18% |
| Nursing and Health Professions | 1 | 4% |
| Social Sciences | 1 | 4% |
| Psychology | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 5 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2014.
All research outputs
#22,760,732
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#1,754
of 2,268 outputs
Outputs of similar age
#282,798
of 322,718 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 23 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,718 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.